“A number of therapeutic uses of cannabis and its derivatives have been postulated from preclinical investigations.
Possible clinical indications include spasticity and pain in multiple sclerosis, cancer-associated nausea and vomiting, cancer pain and HIV neuropathy.
Controversies lie in how to produce, supply and administer cannabinoid products.
Introduction of cannabinoids therapeutically should be supported by a regulatory and educational framework that minimises the risk of harm to patients and the community.
The Regulator of Medicinal Cannabis Bill 2014 is under consideration in Australia to address this.
Nabiximols is the only cannabinoid on the Australian Register of Therapeutic Goods at present, although cannabidiol has been recommended for inclusion in Schedule 4.”